Abstract:Current first-line treatments for Hemophilia A patients are clotting factor replacement or bi-specific antibodies. These treatments require continuous, lifelong infusions, yet many patients have breakthrough bleeds. There remains a high unmet need for safe, effective, and durable therapies. We have developed a liver-directed non-viral in vivo gene insertion approach using the piggyBac® DNA insertion system. Unlike conventional AAV-based gene therapy, our platform enables delivery of large transgenes, the ability to stably and efficiently integrate the therapeutic transgene into the genome, and the potential for re-dosing to titrate to target FVIII activity levels. A key challenge for all gene insertion systems relates to the need to safely and efficiently deliver the transgene DNA. In the current study we evaluated a novel hepatocyte-targeted non-viral platform able to co-deliver both DNA and mRNA with superior safety and specificity relative to the traditional liver-directed LNP concept. We first evaluated a two nanoparticle system using conventional 4-component liver-directed LNPs, with one lipid nanoparticle (LNP) encapsulating the mRNA for the super piggyBac (SPB) transposase (LNP-SPB), and a second LNP encapsulating a plasmid containing the hFVIII transposon DNA (LNP-hFVIII). We subsequently developed a novel co-encapsulated LNP formulation, comprising both SPB mRNA and transposon plasmid DNA (LNP-SPB-hFVIII). In juvenile WT mice we observed a 50% increase in hFVIII antigen expression compared to the dual nanoparticle approach. This was further validated in a severe hemophilia A mouse model (FVIII knock-out). Following a single dose of the co-encapsulated LNP-SPB-hFVIII to adult hemophilia A mice tolerized to human FVIII, we observed ~30% of normal hFVIII expression sustained over the duration of the 7 month study. To further support the concept of re-dosing, we treated immunocompetent adult hemophilia A mice tolerized to human FVIII with repeated administrations every 3 weeks. We observed a dose-proportionate increase in FVIII activity after each administration, reaching an average hFVIII activity of 96% of normal, following 3 repeated doses. Traditional LNPs use several lipid components that typically include an ionizable lipid, cholesterol, a polyethylene glycol (PEG) lipid, and a structural lipid, each with a unique function to effectively encapsulate and deliver the DNA and mRNA required for the piggyBac platform. Cellular transfection of these traditional LNPs has been demonstrated to occur by passive mechanisms such as micropinocytosis or Apolipoprotein E (ApoE)-mediated endocytosis by the low-density lipoprotein receptor (LDLR). However, this can also result in delivery to unwanted cell-types, particularly tissue-resident immune cells. To address this potential failure mode, we explored the addition of a N-Acetylgalactosamine (GalNac)-based targeting ligand to our co-encapsulated LNP formulation (LNP-SPB-hFVIII-G). In immunocompetent animals, targeted LNPs yielded a ~2-3-log reduction in pro-inflammatory serum cytokines (IL-6, IFNɣ) while maintaining high hFVIII expression and no elevation in transaminases (ALT, AST). In conclusion, our results demonstrate the capabilities of the piggyBac DNA insertion system and non-viral approach in providing stable FVIII transgene expression through genomic integration, along with the potential for redosing. Additionally, we have highlighted the tolerability profile of our current generation of liver-targeted non-viral delivery platform. Altogether, these data provide proof-of-principle toward developing an effective and durable therapy for Hemophilia A.

Transient Blockade Of The Inducible Costimulator Pathway Generates Long-Term Tolerance To Factor Viii After Nonviral Gene Transfer Into Hemophilia A Mice

Transient Blockade of Icos Co-Stimulatory Pathways Induces Long-Term Tolerance to Factor Viii Following Nonviral Gene Transfer of Factor Viii Plasmid into Hemophilia A Mice.

Anti-CD3 Antibodies Induce Tolerance to FVIII in Hemophilia A Mice after FVIII Plasmid-Mediated Gene Therapy (89.19)

Anti-Cd3 Antibodies Modulate Anti-Factor Viii Immune Responses in Hemophilia Amice after Factor Viii Plasmid-Mediated Gene Therapy

Cd4(+)Foxp3(+) Regulatory T Cells Confer Long-Term Regulation of Factor Viii-Specific Immune Responses in Plasmid-Mediated Gene Therapy-Treated Hemophilia Mice

hemophilia A mice long-term tolerance for factor VIII following nonviral gene transfer into Transient blockade of the inducible costimulator pathway generates

Reduction of Inhibitor Titres by Infusion of FVIII Gene Transduced Tolerogenic Dendritic Cells in Haemophilic Mice

Induction of factor VIII tolerance by hemophilia gene transfer to eradicate factor VIII inhibitors

Sustaining Expression of B Domain-Deleted Human Factor VIII Mediated by Using Lentiviral Vectors in NOD/SCID Mouse.

A Retrospective Study of the Cytokine Profile Changes in Mice with FVIII Inhibitor Development after Adeno-Associated Virus-Mediated Gene Therapy in a Hemophilia A Mouse Model.

Tolerogenic form of Factor VIII to prevent inhibitor development in the treatment of Hemophilia A

Effective gene therapy for haemophilic mice with pathogenic factor IX antibodies

Enhancing therapeutic efficacy of in vivo platelet-targeted gene therapy in hemophilia A mice

Effective Gene Therapy for Hemophilia a: Novel Re-Dosable Non-Viral Formulation That Provides Stable, and Durable FVIII Expression with Improved Tolerability

Role of Regulatory Cells in Immune Tolerance Induction in Hemophilia A

Intraosseous Delivery of Platelet-Targeted Factor VIII Lentiviral Vector in Humanized NBSGW Mice

The Immune Response to the fVIII Gene Therapy in Preclinical Models

[Immune Tolerance Induction in a Severe Hemophilia A Patient with Inhibitor].

Neutralizing Antibodies Against Factor VIII Can Occur Through a Non-Germinal Center Pathway

Overcoming Hemophilia A Gene Therapy Limitations with an Enhanced Function Factor VIII Variant

Gene Delivery of Activated Factor VII Using Alternative Adeno-Associated Virus Serotype Improves Hemostasis in Hemophiliac Mice with FVIII Inhibitors and Adeno-Associated Virus Neutralizing Antibodies.